Cargando…
Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register
AIMS: To explore the patterns of use of oral glucose‐lowering drugs (OGLDs) in Asian patients with type 2 diabetes (T2D), focusing on sulphonylureas (SUs), and to describe patient profiles according to treatment regimen. METHODS: We conducted a cross‐sectional analysis of data from adults with T2D f...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087907/ https://www.ncbi.nlm.nih.gov/pubmed/36082513 http://dx.doi.org/10.1111/dom.14865 |
_version_ | 1785022456484855808 |
---|---|
author | Lim, Lee‐Ling Lau, Eric S. H. Cheung, Johnny T. K. Chan, Siew Pheng Ji, Linong Lim, Soo Sirinvaravong, Sirinart Unnikrishnan, A. G. Luk, Andrea O. Y. Cortese, Viviana Durocher, Alexandra Chan, Juliana C. N. |
author_facet | Lim, Lee‐Ling Lau, Eric S. H. Cheung, Johnny T. K. Chan, Siew Pheng Ji, Linong Lim, Soo Sirinvaravong, Sirinart Unnikrishnan, A. G. Luk, Andrea O. Y. Cortese, Viviana Durocher, Alexandra Chan, Juliana C. N. |
author_sort | Lim, Lee‐Ling |
collection | PubMed |
description | AIMS: To explore the patterns of use of oral glucose‐lowering drugs (OGLDs) in Asian patients with type 2 diabetes (T2D), focusing on sulphonylureas (SUs), and to describe patient profiles according to treatment regimen. METHODS: We conducted a cross‐sectional analysis of data from adults with T2D from 11 Asian countries/regions with structured assessment enrolled in the prospective Joint Asia Diabetes Evaluation (JADE) register between November 2007 and December 2019. Patients receiving insulin and/or injectable glucagon‐like peptide‐1 receptor agonists were excluded. RESULTS: Amongst 62 512 patients (mean ± standard deviation age: 57.3 ± 11.8 years; 53.6% men), 54 783 (87.6%) were treated with OGLDs at enrolment. Most received one (37.5%) or two (44.2%) OGLDs. In the entire cohort, 59.4% of treated patients received SU‐based therapy with variations amongst countries/regions. Overall, 79.5% of SU regimens were based on SUs plus metformin, and 22.1% on SUs plus dipeptidyl peptidase‐4 inhibitors. Among SU users, gliclazide was most commonly prescribed (46.7%), followed by glimepiride (40.0%) and glibenclamide (8.1%). More gliclazide users entered the cohort with glycated haemoglobin levels <53 mmol/mol (7%) than non‐gliclazide SU users (odds ratio [OR] 1.09, 95% CI 1.02‐1.17), with less frequent self‐reported hypoglycaemia in the 3 months before registration (OR 0.81, 95% CI 0.72‐0.92; adjusted for sociodemographic factors, cardiometabolic risk factors, complications, use of other OGLDs, country/region and year of registration). CONCLUSION: In Asia, SUs are a popular OGLD class, often combined with metformin. Good glycaemic control and safety profiles associated with the use of SUs, including gliclazide, support their position as a key treatment option in patients with T2D. |
format | Online Article Text |
id | pubmed-10087907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-100879072023-04-12 Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register Lim, Lee‐Ling Lau, Eric S. H. Cheung, Johnny T. K. Chan, Siew Pheng Ji, Linong Lim, Soo Sirinvaravong, Sirinart Unnikrishnan, A. G. Luk, Andrea O. Y. Cortese, Viviana Durocher, Alexandra Chan, Juliana C. N. Diabetes Obes Metab Original Articles AIMS: To explore the patterns of use of oral glucose‐lowering drugs (OGLDs) in Asian patients with type 2 diabetes (T2D), focusing on sulphonylureas (SUs), and to describe patient profiles according to treatment regimen. METHODS: We conducted a cross‐sectional analysis of data from adults with T2D from 11 Asian countries/regions with structured assessment enrolled in the prospective Joint Asia Diabetes Evaluation (JADE) register between November 2007 and December 2019. Patients receiving insulin and/or injectable glucagon‐like peptide‐1 receptor agonists were excluded. RESULTS: Amongst 62 512 patients (mean ± standard deviation age: 57.3 ± 11.8 years; 53.6% men), 54 783 (87.6%) were treated with OGLDs at enrolment. Most received one (37.5%) or two (44.2%) OGLDs. In the entire cohort, 59.4% of treated patients received SU‐based therapy with variations amongst countries/regions. Overall, 79.5% of SU regimens were based on SUs plus metformin, and 22.1% on SUs plus dipeptidyl peptidase‐4 inhibitors. Among SU users, gliclazide was most commonly prescribed (46.7%), followed by glimepiride (40.0%) and glibenclamide (8.1%). More gliclazide users entered the cohort with glycated haemoglobin levels <53 mmol/mol (7%) than non‐gliclazide SU users (odds ratio [OR] 1.09, 95% CI 1.02‐1.17), with less frequent self‐reported hypoglycaemia in the 3 months before registration (OR 0.81, 95% CI 0.72‐0.92; adjusted for sociodemographic factors, cardiometabolic risk factors, complications, use of other OGLDs, country/region and year of registration). CONCLUSION: In Asia, SUs are a popular OGLD class, often combined with metformin. Good glycaemic control and safety profiles associated with the use of SUs, including gliclazide, support their position as a key treatment option in patients with T2D. Blackwell Publishing Ltd 2022-09-26 2023-01 /pmc/articles/PMC10087907/ /pubmed/36082513 http://dx.doi.org/10.1111/dom.14865 Text en © 2022 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Lim, Lee‐Ling Lau, Eric S. H. Cheung, Johnny T. K. Chan, Siew Pheng Ji, Linong Lim, Soo Sirinvaravong, Sirinart Unnikrishnan, A. G. Luk, Andrea O. Y. Cortese, Viviana Durocher, Alexandra Chan, Juliana C. N. Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register |
title | Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register |
title_full | Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register |
title_fullStr | Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register |
title_full_unstemmed | Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register |
title_short | Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register |
title_sort | real‐world usage of sulphonylureas in asian patients with type 2 diabetes using the joint asia diabetes evaluation (jade) register |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087907/ https://www.ncbi.nlm.nih.gov/pubmed/36082513 http://dx.doi.org/10.1111/dom.14865 |
work_keys_str_mv | AT limleeling realworldusageofsulphonylureasinasianpatientswithtype2diabetesusingthejointasiadiabetesevaluationjaderegister AT lauericsh realworldusageofsulphonylureasinasianpatientswithtype2diabetesusingthejointasiadiabetesevaluationjaderegister AT cheungjohnnytk realworldusageofsulphonylureasinasianpatientswithtype2diabetesusingthejointasiadiabetesevaluationjaderegister AT chansiewpheng realworldusageofsulphonylureasinasianpatientswithtype2diabetesusingthejointasiadiabetesevaluationjaderegister AT jilinong realworldusageofsulphonylureasinasianpatientswithtype2diabetesusingthejointasiadiabetesevaluationjaderegister AT limsoo realworldusageofsulphonylureasinasianpatientswithtype2diabetesusingthejointasiadiabetesevaluationjaderegister AT sirinvaravongsirinart realworldusageofsulphonylureasinasianpatientswithtype2diabetesusingthejointasiadiabetesevaluationjaderegister AT unnikrishnanag realworldusageofsulphonylureasinasianpatientswithtype2diabetesusingthejointasiadiabetesevaluationjaderegister AT lukandreaoy realworldusageofsulphonylureasinasianpatientswithtype2diabetesusingthejointasiadiabetesevaluationjaderegister AT corteseviviana realworldusageofsulphonylureasinasianpatientswithtype2diabetesusingthejointasiadiabetesevaluationjaderegister AT durocheralexandra realworldusageofsulphonylureasinasianpatientswithtype2diabetesusingthejointasiadiabetesevaluationjaderegister AT chanjulianacn realworldusageofsulphonylureasinasianpatientswithtype2diabetesusingthejointasiadiabetesevaluationjaderegister |